The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 28, 2012
Filed:
Mar. 07, 2007
Timothy Thomson Okatsu, Barcelona, ES;
Johanna Scheper Sigmund, Barcelona, ES;
Ángel Messeguer Peypoch, Barcelona, ES;
Ángel Ramírez Ortiz, Móstoles, ES;
María Luz Ortiz Melguizo, Legal Representative, Móstoles, ES;
MA Carmen Fabrega Claveria, Legal Representative, Barcelona, ES;
Gloria Sanclimens Pérez DE Rozas, Barcelona, ES;
Isabel Masip Masip, Barcelona, ES;
Alejandra Moure Fernández, Barcelona, ES;
Domingo González Ruiz, Cantoblanco, ES;
Antonio Morreale DE León, Cantoblanco, ES;
Timothy Thomson Okatsu, Barcelona, ES;
Johanna Scheper Sigmund, Barcelona, ES;
Ángel Messeguer Peypoch, Barcelona, ES;
Ángel Ramírez Ortiz, Móstoles, ES;
María Luz Ortiz Melguizo, legal representative, Móstoles, ES;
Ma Carmen Fabrega Claveria, legal representative, Barcelona, ES;
Gloria Sanclimens Pérez de Rozas, Barcelona, ES;
Isabel Masip Masip, Barcelona, ES;
Alejandra Moure Fernández, Barcelona, ES;
Domingo González Ruiz, Cantoblanco, ES;
Antonio Morreale de León, Cantoblanco, ES;
Consejo Superior de Investigaciones Cientificas, Madrid, ES;
Abstract
The invention relates to a compound (I) wherein R is a heterocyclyl radical; Rand Rare independently H or alkyl; Ris H, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl; Rand Rare independently H or alkyl; q is a number selected from 0 and 1; and the salts, solvates, prodrugs or stereoisomers thereof having inhibitory activity for UBC13-UEV interactions and which can be used in the production of pharmaceutical compositions intended for antitumor therapy or the treatment and/or prophylaxis of diseases associated to metabolic pathways involving the UBC13 enzyme, metabolic pathways involving transcriptional factor NF-κB, or pathways involving PCNA or RAD6.R—(CRR)-CO—N(R)—C(RR)—CO—NH  (I)
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile